<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00648154</url>
  </required_header>
  <id_info>
    <org_study_id>LETR-05123</org_study_id>
    <nct_id>NCT00648154</nct_id>
  </id_info>
  <brief_title>Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg</brief_title>
  <official_title>Single-Dose Fed Bioequivalence Study of Letrozole Tablets (2.5 mg; Mylan) and Femara® Tablets (2.5 mg; Novartis) in Healthy Postmenopausal Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mylan Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The objective of this study was to investigate the bioequivalence of Mylan's letrozole 2.5 mg&#xD;
      tablets to Novartis' Femara® 2.5 mg tablets following a single, oral 2.5 mg (1 x 2.5 mg) dose&#xD;
      administered under fed conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The 90% confidence interval for the LSMeans ratio of CPEAK, AUCL, and AUCI for the test and reference product should be between 80.00% and 125.00% for the natural log-transformed data.</measure>
    <time_frame>Blood collections through 216 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole Tablets 2.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Femara® Tablets 2.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole Tablets 2.5 mg</intervention_name>
    <description>2.5mg, single dose fed</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Femara® Tablets 2.5 mg</intervention_name>
    <description>2.5mg, single dose fed</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 40 years or older.&#xD;
&#xD;
          2. Sex: Females only.&#xD;
&#xD;
          3. Weight: At least 52 kg (115 lbs) and within 30% of Ideal Body Weight (IBW), as&#xD;
             referenced by the Table of &quot;&quot;Desirable Weights of Adults&quot;&quot; from Metropolitan Life&#xD;
             Insurance Company, 1999 (See Part II: ADMINISTRATIVE ASPECTS OF HUMAN BIOAVAILABILITY&#xD;
             PROTOCOLS).&#xD;
&#xD;
          4. Absence of menses for one year for postmenopausal subjects, or at least 6 weeks for&#xD;
             oophorectomized subjects. (For oophorectomized subjects, an operative report&#xD;
             documenting bilateral oophorectomy and surgical pathology report documenting the&#xD;
             absence of malignant disease.)&#xD;
&#xD;
          5. Baseline FSH and 17β-estradiol serum levels consistent with postmenopausal status&#xD;
             confirmed within 72 hours of initiation of study medication (FSH greater than or equal&#xD;
             to 40 mIU/mL; 17β-estradiol less than or equal to 31 pg/mL).&#xD;
&#xD;
          6. All subjects should be judged normal and healthy during a pre-study medical evaluation&#xD;
             (physical examination, laboratory evaluation, 12-lead ECG, Hepatitis B, Hepatitis C&#xD;
             and HIV tests, and urine drug screen including amphetamine, barbiturates,&#xD;
             benzodiazepines, cannabinoid, cocaine, opiates, phencyclidine, and methadone)&#xD;
             performed within 21 days of the initial dose of study medication.&#xD;
&#xD;
          7. The physical examination shall include pelvic and breast exams.&#xD;
&#xD;
               1. Pelvic findings should be consistent with hypoestrogenemia.&#xD;
&#xD;
               2. A mammogram will be required if not performed within the last 12 months.&#xD;
&#xD;
               3. A Papanicolaou (&quot;Pap&quot;) smear will be required on subjects with an intact uterus&#xD;
                  and cervix if not performed within the last 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Institutionalized subjects will not be used.&#xD;
&#xD;
          2. Social Habits:&#xD;
&#xD;
               1. Use of any tobacco-containing products within 1 year of start of study.&#xD;
&#xD;
               2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage&#xD;
                  within the 48 hours prior to the initial dose of study medication.&#xD;
&#xD;
               3. Ingestion of any vitamins or herbal products within 7 days prior to the initial&#xD;
                  dose of the study medication.&#xD;
&#xD;
               4. Any recent, significant change in dietary or exercise habits.&#xD;
&#xD;
               5. A positive test for any drug included in the urine drug screen.&#xD;
&#xD;
               6. History of drug and/or alcohol abuse.&#xD;
&#xD;
          3. Medications:&#xD;
&#xD;
               1. Use of any prescription or over-the-counter (OTC) medications within the 14 days&#xD;
                  prior to the initial dose of study medication.&#xD;
&#xD;
               2. Use of any medication known to alter hepatic enzyme activity within 28 days prior&#xD;
                  to the initial dose of study medication.&#xD;
&#xD;
               3. Use hormonal replacement therapy within 3 months prior to the initial dose of&#xD;
                  study medication.&#xD;
&#xD;
          4. Diseases:&#xD;
&#xD;
               1. History of any significant chronic disease such as (but not limited to): 1.&#xD;
                  Thrombotic disorders. 2. Coronary artery or cerebrovascular disease. 3. Liver,&#xD;
                  kidney or gallbladder dysfunction/disorder(s). 4. Diabetes or any other&#xD;
                  endocrinological disease. 5. Estrogen-dependent neoplasia. 6. Postmenopausal&#xD;
                  uterine bleeding. 7. Endometrial hyperplasia.&#xD;
&#xD;
               2. Acute illness at the time of either the pre-study medical evaluation or dosing.&#xD;
&#xD;
               3. A positive HIV, Hepatitis B, or Hepatitis C test.&#xD;
&#xD;
          5. Abnormal and clinically significant laboratory test results:&#xD;
&#xD;
               1. Clinically significant deviation from the Guide to Clinically Relevant&#xD;
                  Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).&#xD;
&#xD;
               2. Abnormal and clinically relevant ECG tracing.&#xD;
&#xD;
          6. Donation or loss of a significant volume of blood or plasma (&gt; 450 mL) within 28 days&#xD;
             prior to the initial dose of study medication.&#xD;
&#xD;
          7. Subjects who have received an investigational drug within 30 days prior to the initial&#xD;
             dose of study medication.&#xD;
&#xD;
          8. Allergy or hypersensitivity to letrozole, any of the inactive ingredients.&#xD;
&#xD;
          9. History of difficulties in swallowing, or any gastrointestinal disease which could&#xD;
             affect the drug absorption.&#xD;
&#xD;
         10. Consumption of grapefruit or grapefruit containing products within 7 days of drug&#xD;
             administration.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Galitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC International</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC International</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mpibiostudies.com</url>
    <description>Mylan Pharmaceuticals Inc. - Clinical Trial Results</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Recalls, Market Withdrawals and Safety Alerts</description>
  </link>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>March 30, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>November 30, 2009</last_update_submitted>
  <last_update_submitted_qc>November 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Wayne Talton</name_title>
    <organization>Mylan Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

